Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2025 Jul 8:rs.3.rs-7015694.
doi: 10.21203/rs.3.rs-7015694/v1.

Revisiting Centiloids using AI

Affiliations

Revisiting Centiloids using AI

Pierrick Bourgeat et al. Res Sq. .

Abstract

The Centiloid scale is the standard for Amyloid ( A β ) PET quantification, widely used in research, clinical settings, and trial stratification. However, variability between tracers and scanners remains a challenge. This study introduces DeepSUVR, a deep learning method to correct Centiloid quantification, by penalising implausible longitudinal trajectories during training. The model was trained using data from 2,098 participants (6,762 A β PET scans) in AIBL/ADNI and validated using 15,806 A β PET scans from 10,543 participants across 10 external datasets. DeepSUVR increased correlation between tracers, and reduced variability in the A β -negatives. It showed the strongest association with cognition, highest AUC against visual reads and best longitudinal consistency between studies. DeepSUVR also increased the effect size for detecting lower Centiloid increase per year in the A4 study. DeepSUVR advances A β PET quantification, outperforming standard approaches, which is particularly important for consistent decision making and to detect subtle and early changes in clinical interventions.

PubMed Disclaimer

Conflict of interest statement

Additional Declarations: Yes there is potential Competing Interest. I am an inventor on a patent application related to the technology described in the manuscript: PCT/AU2024/051378.

Figures

Figure 1
Figure 1
Scatterplots comparing PiB vs FBP in the OASIS Head-to-Head (H2H) dataset (left) and each 18F-Tracer versus PIB in the GAAIN Head-to-Head Calibration dataset (Right), using CLStd (top) and CLDS (bottom). The correlation between each pair of tracers is assessed using the coefficient of determination R2. The standard deviation in the Young Controls (YC) for each tracer is denoted as σ(TracerYC. Note that for FMM, one YC with a CL>20 on both PIB and FMM across all methods was determined to be an outlier and excluded from the standard deviation calculation.
Figure 2
Figure 2
Histogram distribution of Centiloid values across the 12 cohorts using the Standard and DeepSUVR CL methods. For each approach, a Gaussian mixture is fitted to the distribution of Centiloid values of each study (top) and each tracer (bottom), and the average mean [min,max] and average standard deviation [min,max] of the first peak across all studies (tracer respectively) is reported. The dashed lines mark the 0CL and 20CL. Significantly lower variability in the means and standard deviations when comparing CLDS to CLStd across studies/tracers based on bootstrapping are indicated using: *** (p<0.001) for lower variabilities in the means and ### (p<0.001) for lower variabilities in the standard deviations.
Figure 3
Figure 3
Rate of CL change per year compared to mean CL computed from the 2 training (AIBL/ADNI) cohorts (a.), the 7 testing cohorts with longitudinal data (A4-Placebo, AMYPAD, HABS-HD, OASIS, DLBS, MCSA, WRAP) (b.) and the placebo and treatment arms of the A4 Study (c.) using the Standard (left) and DeepSUVR CL (right) methods. Each point represents the mean and rate of change between a pair of consecutive visits from the same participant. Each curve shows a 5th order polynomial fitted to each study. The Spearman rank correlation between Mean CL and CL/Year is denoted using r (a. and b.), while the effect size of the CL accumulation per year between the 2 arms of the A4 study is denoted using Cohen’s d (c.). The vertical dashed lines mark the 0CL and 20CL, while the horizontal dashed line mark the 0CL/Year. Significantly higher correlation or effect size when comparing CLDS to CLStd across studies/tracers based on bootstrapping are indicated using: *** p<0.001.
Figure 4
Figure 4
Axial views of the Standard CL reference mask (row1) and the new reference mask derived from DeepSUVR (row2), the Standard CL target mask (row3) and the new target mask derived from DeepSUVR (row4)
Figure 5
Figure 5
Framework used for training (top) and inference (bottom) using DeepSUVR. While training requires pairs of images from the same participant, inference is run on single images.
Figure 6
Figure 6
The penalties in the loss functions used to constrain the model: for each pairs of TPs, penalise the Centiloid decreasing over time (a); penalise the distance to the population curve of Mean CL vs Rate of change (b); for each batch, penalise the regression line of the standard CL vs corrected CL when it deviates from slope=1 and intercept=0.

References

    1. Andrews D., Ducharme S., Chertkow H., Sormani M.P., Collins D.L., 2025. The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect. Alzheimers Dement. 21, e14467. 10.1002/alz.14467 - DOI - PMC - PubMed
    1. Becker G.A., Ichise M., Barthel H., Luthardt J., Patt M., Seese A., Schultze-Mosgau M., Rohde B., Gertz H.-J., Reininger C., Sabri O., 2013. PET Quantification of 18F-Florbetaben Binding to β-Amyloid Deposits in Human Brains. J. Nucl. Med. 54, 723–731. 10.2967/jnumed.112.107185 - DOI - PubMed
    1. Betthauser T.J., Bilgel M., Koscik R.L., Jedynak B.M., An Y., Kellett K.A., Moghekar A., Jonaitis E.M., Stone C.K., Engelman C.D., Asthana S., Christian B.T., Wong D.F., Albert M., Resnick S.M., Johnson S.C., Alzheimer’s Disease Neuroimaging Initiative, 2022. Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts. Brain J. Neurol. 145, 4065–4079. 10.1093/brain/awac213 - DOI - PMC - PubMed
    1. Bollack A., Collij L.E., García D.V., Shekari M., Altomare D., Payoux P., Dubois B., Grau-Rivera O., Boada M., Marquié M., Nordberg A., Walker Z., Scheltens P., Schöll M., Wolz R., Schott J.M., Gismondi R., Stephens A., Buckley C., Frisoni G.B., Hanseeuw B., Visser P.J., Vandenberghe R., Drzezga A., Yaqub M., Boellaard R., Gispert J.D., Markiewicz P., Cash D.M., Farrar G., Barkhof F., Consortium A., 2024. Investigating reliable amyloid accumulation in Centiloids: Results from the AMYPAD Prognostic and Natural History Study. Alzheimers Dement. 20, 3429–3441. 10.1002/alz.13761 - DOI - PMC - PubMed
    1. Bollack A., Markiewicz P.J., Wink A.M., Prosser L., Lilja J., Bourgeat P., Schott J.M., Coath W., Collij L.E., Pemberton H.G., Farrar G., Barkhof F., Cash D.M., 2023a. Evaluation of novel data-driven metrics of amyloid β deposition for longitudinal PET studies. NeuroImage 280, 120313. 10.1016/j.neuroimage.2023.120313 - DOI - PubMed

Publication types

LinkOut - more resources